A 6‐month randomized controlled trial for vitamin E supplementation in pediatric patients with Gaucher disease: Effect on oxidative stress, disease severity and hepatic complications
Journal of Inherited Metabolic Disease · 2025
DOI: 10.1002/jimd.12792 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Amira Abdel Moneam Adly und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Oxidative Stress, Vitamin E, Gaucher Disease, Antioxidants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Enzymatic deficiency in Gaucher disease (GD) may induce oxidative stress. Vitamin E is the nature's most effective lipid‐soluble antioxidant. This prospective clinical trial assessed the oxidant‐antioxidant status in Egyptian patients with GD and the efficacy and safety and of vitamin E as an adjuvant antioxidant therapy. Forty children and adolescents with GD on stable doses of enzyme replacement therapy (ERT) were enrolled. Abdominal ultrasonography and transient elastography were performed. Malondialdehyde (MDA), vitamin E, and antioxidant enzymes (reduced glutathione [GSH], superoxide dismutase [SOD], glutathione peroxidase [GPx], and peroxiredoxin 2 [PRDX2]) were assessed. Patients were compared with 40 age‐ and sex‐matched healthy controls. Patients with GD were randomized either to receive oral vitamin E for 6 months or not. All patients with GD had significantly higher MDA levels with lower levels of vitamin E and antioxidant enzymes compared with healthy controls ( p < 0.001). Vitamin E and PRDX2 were negatively correlated to severity score index (SSI), lyso GL1, and MDA. After 6 months of vitamin E supplementation, SSI and liver and spleen volumes and liver stiffness were significantly lower. Lyso GL1 and MDA were significantly decreased post‐vitamin E therapy while antioxidant enzymes were significantly higher compared with baseline levels and with patients without vitamin E therapy. Oxidative stress is related to disease severity in pediatric patients with GD. A 6‐month vitamin E supplementation for those patients represents a safe therapeutic adjuvant agent increasing the efficacy of ERT, reducing oxidative stress, and improving outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatrics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Biochemistry Department, Biotechnology Institute, National Research Centre, Cairo, Egypt.
- Endemic Medicine and Hepatogasteroenterology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
ORCID-Profile: Amira Abdel Moneam Adly, Eman Abdel Rahman Ismail
Zitieren
APA
Adly, A. A. M., Ismail, E. A. R., Ibrahim, F. A., Atef, M., El Sayed, K. A., & Aly, N. H. (2025). A 6‐month randomized controlled trial for vitamin E supplementation in pediatric patients with Gaucher disease: Effect on oxidative stress, disease severity and hepatic complications. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12792
Vancouver
Adly AAM, Ismail EAR, Ibrahim FA, Atef M, El Sayed KA, Aly NH. A 6‐month randomized controlled trial for vitamin E supplementation in pediatric patients with Gaucher disease: Effect on oxidative stress, disease severity and hepatic complications. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.12792
BibTeX
@article{Adly2025,
author = {Adly, Amira Abdel Moneam and Ismail, Eman Abdel Rahman and Ibrahim, Fatma A and Atef, Mira and El Sayed, Khaled Anwar and Aly, Nihal Hussien},
title = {A 6‐month randomized controlled trial for vitamin E supplementation in pediatric patients with Gaucher disease: Effect on oxidative stress, disease severity and hepatic complications},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
doi = {10.1002/jimd.12792}
}
EUVIMED